Molecular mechanisms for alcoholic hepatitis based on analysis of gene expression profile

Hepatitis Monthly

Volumn 15, Issue 5, 2015, Pages

  Liu, Minghui ^a   Dou, Yuchang ^a   Sun, Ran ^a   Zhang, Yonggui ^a   Liu, Yansong ^a  

^a CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Alcoholic hepatitis; Disease; Protein protein interaction map

Indexed keywords

ALPHA TROPOMYOSIN; GLUTAMINASE; NUCLEOSIDE DIPHOSPHATE KINASE A; PEPTIDYLPROLYL ISOMERASE; SCLEROPROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SOX4; TRANSCRIPTION FACTOR SOX9; UBIQUITIN THIOLESTERASE; VON WILLEBRAND FACTOR;

ALCOHOL LIVER DISEASE; AMINO ACID METABOLISM; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION; GENE ONTOLOGY; GLUCOSE METABOLISM; HUMAN; LIVER BIOPSY; LIVER INJURY; MICROARRAY ANALYSIS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; ONCOGENE; OXIDATIVE STRESS; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SCORING SYSTEM; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84990299008     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.15(5)2015.27336     Document Type: Article

References (42)

1. Nagata K, Suzuki H, Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci. 2007;32(5):453–68.
2. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360(26):2758–69.
3. Spengler EK, Dunkelberg J, Schey R. Alcoholic hepatitis: current management. Dig Dis Sci. 2014;59(10):2357–66.
4. Singal AK, Walia I, Singal A, Soloway RD. Corticosteroids and pentoxifylline for the treatment of alcoholic hepatitis: Current status. World J Hepatol. 2011;3(8):205–10.
5. Chayanupatkul M, Liangpunsakul S. Alcoholic hepatitis: a comprehensive review of pathogenesis and treatment. World J Gastroenterol. 2014;20(20):6279–86.
6. Bird G. Interleukin-8 in alcoholic liver disease. Acta Gastroenterol Belg. 1994;57(3-4):255–9.
7. Serviddio G, Bellanti F, Sastre J, Vendemiale G, Altomare E. Targeting mitochondria: a new promising approach for the treatment of liver diseases. Curr Med Chem. 2010;17(22):2325–37.
8. Abangah G, Yousefi A, Asadollahi R, Veisani Y, Rahimifar P, Alizadeh S. Correlation of Body Mass Index and Serum Parameters With Ultrasonographic Grade of Fatty Change in Non-alcoholic Fatty Liver Disease. Iran Red Crescent Med J. 2014;16(1).
9. O'Shea RS, Dasarathy S, McCullough AJ, Practice Guideline Committee of the American Association for the Study of Liver D, Practice Parameters Committee of the American College of G. Alcoholic liver disease. Hepatology. 2010;51(1):307–28.
10. Alavian SM. Networking for Overcoming on Viral Hepatitis in Middle East and Central Asia:" Asian Hepatitis Network. Hepat Mon. 2007;7(4):181–2.
11. Affo S, Dominguez M, Lozano JJ, Sancho-Bru P, Rodrigo-Torres D, Morales-Ibanez O, et al. Transcriptome analysis identifies TNF superfamily receptors as potential therapeutic targets in alcoholic hepatitis. Gut. 2013;62(3):452–60.
12. Gautier L, Cope L, Bolstad BM, Irizarry RA. affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307–15.
13. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–64.
14. Zhao M, Sun J, Zhao Z. TSGene: a web resource for tumor suppressor genes. Nucleic Acids Res. 2013;41(Database issue):D970–6.
15. Chen JS, Hung WS, Chan HH, Tsai SJ, Sun HS. In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma. Bioinformatics. 2013;29(4):420–7.
16. Arakawa K, Kono N, Yamada Y, Mori H, Tomita M. KEGG-based pathway visualization tool for complex omics data. In Silico Biol. 2005;5(4):419–23.
17. Hulsegge I, Kommadath A, Smits MA. Globaltest and GOEAST: two different approaches for Gene Ontology analysis. BMC Proc. 2009;3(Suppl 4):S10.
18. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
19. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41(Database issue):D808–15.
20. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, Lindemann P, et al. Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27(8):402–9.
21. Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int. 2002;40(6):475–86.
22. Mantena SK, King AL, Andringa KK, Landar A, Darley-Usmar V, Bailey SM. Novel interactions of mitochondria and reactive oxygen/ nitrogen species in alcohol mediated liver disease. World J Gastroenterol. 2007;13(37):4967–73.
23. Bailey SM. A review of the role of reactive oxygen and nitrogen species in alcohol-induced mitochondrial dysfunction. Free Radic Res. 2003;37(6):585–96.
24. Andringa KK, King AL, Eccleston HB, Mantena SK, Landar A, Jhala NC, et al. Analysis of the liver mitochondrial proteome in response to ethanol and S-adenosylmethionine treatments: novel molecular targets of disease and hepatoprotection. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):G732–45.
25. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radic Biol Med. 2003;34(1):1–10.
26. Wu D, Cederbaum AI. Oxidative stress and alcoholic liver disease. Semin Liver Dis. 2009;29(2):141–54.
27. Xie L, Yui J, Hatori A, Yamasaki T, Kumata K, Wakizaka H, et al. Translocator protein (18 kDa), a potential molecular imaging biomarker for non-invasively distinguishing non-alcoholic fatty liver disease. J Hepatol. 2012;57(5):1076–82.
28. Price ER, Zydowsky LD, Jin MJ, Baker CH, McKeon FD, Walsh CT. Human cyclophilin B: a second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence. Proc Natl Acad Sci U S A. 1991;88(5):1903–7.
29. Yurchenko V, O'Connor M, Dai WW, Guo H, Toole B, Sherry B, et al. CD147 is a signaling receptor for cyclophilin B. Biochem Biophys Res Commun. 2001;288(4):786–8.
30. Zhang DW, Zhao YX, Wei D, Li YL, Zhang Y, Wu J, et al. HAb18G/ CD147 promotes activation of hepatic stellate cells and is a target for antibody therapy of liver fibrosis. J Hepatol. 2012;57(6):1283–91.
31. Forman HJ, Fukuto JM, Torres M. Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers. Am J Physiol Cell Physiol. 2004;287(2):C246–56.
32. Kohchi C, Inagawa H, Nishizawa T, Soma G. ROS and innate immunity. Anticancer Res. 2009;29(3):817–21.
33. Fischer R, Schmitt M, Bode JG, Haussinger D. Expression of the peripheral-type benzodiazepine receptor and apoptosis induction in hepatic stellate cells. Gastroenterology. 2001;120(5):1212–26.
34. Stahl JA, Leone A, Rosengard AM, Porter L, King CR, Steeg PS. Identification of a second human nm23 gene, nm23-H2. Cancer Res. 1991;51(1):445–9.
35. Lee MJ, Xu DY, Li H, Yu GR, Leem SH, Chu IS, et al. Pro-oncogenic potential of NM23-H2 in hepatocellular carcinoma. Exp Mol Med. 2012;44(3):214–24.
36. Ohneda K, Fukuda M, Shimada N, Ishikawa N, Ichou T, Kaji K, et al. Increased expression of nucleoside diphosphate kinases/nm23 in human diploid fibroblasts transformed by SV40 large T antigen or 60Co irradiation. FEBS Lett. 1994;348(3):273–7.
37. Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 1988;80(3):200–4.
38. Palmieri D, Horak CE, Lee JH, Halverson DO, Steeg PS. Translational approaches using metastasis suppressor genes. J Bioenerg Biomembr. 2006;38(3-4):151–61.
39. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12(8):895–904.
40. Iizuka N, Oka M, Noma T, Nakazawa A, Hirose K, Suzuki T. NM23- H1 and NM23-H2 messenger RNA abundance in human hepatocellular carcinoma. Cancer Res. 1995;55(3):652–7.
41. Yamaguchi A, Urano T, Goi T, Takeuchi K, Niimoto S, Nakagawara G, et al. Expression of human nm23-H1 and nm23-H2 proteins in hepatocellular carcinoma. Cancer. 1994;73(9):2280–4.
42. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S87–96.